Email:
sales@chinesepeptide.com
Jan 25, 2019
Nucleic AcidHub-2023 China Nucleic Acid Drug and Novel Vaccine Industry Conference was successfully concluded in Wuhan, China on June 15-16, 2023! The conference focuses on core topics such as progress in nucleic acid drug R&D, delivery platforms, RNA process technology, scientific frontier and basic research, progress in mRNA vaccine research and development, exploring more vaccine research and progress, tumor vaccine technology and development, etc. It brings together heavyweight guests from the head companies of nucleic acid vaccines and related people from the whole upstream and downstream industry chain to discuss and exchange industry hotspots, showcase the latest cutting-edge technology, and devote to Promote the technological innovation and industrial integration of nucleic acid vaccine research and development.
Dr. Bing Feng, Senior Director of Oligonucleotide Division of Chinese peptide company was invited to participate in this conference, and as a roundtable discussant in the Nucleic Acid and Peptide Drug Development Forum, he conducted academic exchanges with experts and industry colleagues on the spot, with a strong academic atmosphere.
Introduction: Doctor of Science, Academy of Military Medical Sciences, Chief Engineer of China National Nucleic Acid Drug Engineering Center, sub-project leader of China National major project "Nucleic acid drug Innovative varieties Research and accurate modification and New packaged generic technology (2017ZX09303013)". Currently, he is the senior director of oligonucleotide Division of Zhongpeptide Biochemistry Co., LTD., mainly responsible for the construction of nucleic acid pharmaceutical platform, the establishment of oligonucleotide R&D and production team, as well as project management and production.
The exhibitors of Chinese peptide company had a lively discussion with all the guests and industry colleagues presenting the latest research progress in the leading fields of peptide and nucleic acid CRDMO services.
Founded in 2001, Chinese peptide company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.
The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.
